Science Explorer Back to mapMap
Discussion
Institution · Desmond Tutu HIV Foundation

Most cited papers from Desmond Tutu HIV Foundation

Desmond Tutu HIV Foundation

What are the most cited papers from Desmond Tutu HIV Foundation?

The most cited paper from Desmond Tutu HIV Foundation is "Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men" (Robert M. Grant et al., 2010), with 5,186 citations. Next come "Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study" (1,259) and "Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men" (1,057).

Showing 50 of 60 papers. Every paper with more than 254 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men Robert M. Grant et al. · New England Journal of Medicine Open access 23 Nov 2010 5,186
2 Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study Robert M. Grant et al. · The Lancet Infectious Diseases Open access 22 Jul 2014 1,259
3 Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men Peter L. Anderson, David V. Glidden, Albert Liu et al. · Science Translational Medicine Open access 12 Sep 2012 1,057
4 Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society—Lancet Commission Linda‐Gail Bekker et al. · The Lancet Open access Jul 2018 779
5 Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women Jared M. Baeten et al. · New England Journal of Medicine Open access 22 Feb 2016 774
6 Tuberculosis Stephen D Lawn, Alimuddin I. Zumla · The Lancet 12 May 2011 761
7 Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings Graeme Meintjes, Stephen D Lawn, Fabio Scano et al. · The Lancet Infectious Diseases Open access 22 Jul 2008 749
8 The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis Keertan Dheda et al. · The Lancet Respiratory Medicine 23 Mar 2017 706
9 Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination Elisa Nemes et al. · New England Journal of Medicine Open access 11 Jul 2018 675
10 Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa Stephen D Lawn, Anthony David Harries, Xavier Anglaret et al. · AIDS Open access 10 Sep 2008 648
11 Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa Shirley Collie, Jared Champion, Harry Moultrie et al. · New England Journal of Medicine Open access 29 Dec 2021 646
12 T cell responses to SARS-CoV-2 spike cross-recognize Omicron Roanne S. Keeton et al. · Nature Open access 31 Jan 2022 626
13 Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm Melissa D. Simek et al. · Journal of Virology Open access 13 May 2009 599
14 Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial Sinéad Delany‐Moretlwe et al. · The Lancet Open access109 authors Apr 2022 584
15 Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition Lawrence Corey et al. · New England Journal of Medicine Open access 17 Mar 2021 567
16 HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response Salim S. Abdool Karim, Gavin Churchyard, Quarraisha Abdool Karim et al. · The Lancet Open access 26 Aug 2009 550
17 Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals Stephen D Lawn, Linda‐Gail Bekker, Robert F. Miller · The Lancet Infectious Diseases 25 May 2005 548
18 Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism Mi‐Jeong Kim, Helen Wainwright, Michael Louis Locketz et al. · EMBO Molecular Medicine Open access Jul 2010 516
19 Xpert ® MTB/RIF Assay: Development, Evaluation and Implementation of a New Rapid Molecular Diagnostic for Tuberculosis and Rifampicin Resistance Stephen D Lawn, Mark Patrick Nicol · Future Microbiology Open access Sep 2011 490
20 Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women Annalene M. Nel et al. · New England Journal of Medicine Open access 30 Nov 2016 480
21 Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test Stephen D Lawn, Peter Mwaba, Matthew Bates et al. · The Lancet Infectious Diseases Open access 24 Mar 2013 464
22 Life Expectancies of South African Adults Starting Antiretroviral Treatment: Collaborative Analysis of Cohort Studies Leigh Francis Johnson, Joël Mossong, Rob Dorrington et al. · PLoS Medicine Open access 9 Apr 2013 450
23 A reduction in marine primary productivity driven by rapid warming over the tropical Indian Ocean Mathew Koll Roxy, Aditi Modi, Raghu G. Murtugudde et al. · Geophysical Research Letters Open access 19 Dec 2015 435
24 Antiretroviral Therapy for Prevention of Tuberculosis in Adults with HIV: A Systematic Review and Meta-Analysis Amitabh Bipin Suthar, Stephen D Lawn, Julia del Amo et al. · PLoS Medicine ReviewOpen access 24 Jul 2012 419
25 Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-analysis of Observational Studies Haileyesus Getahun, Wanitchaya Kittikraisak, Charles M. Heilig et al. · PLoS Medicine ReviewOpen access 18 Jan 2011 418
26 Reimagining HIV service delivery: the role of differentiated care from prevention to suppression Anna Grimsrud, Helen Bygrave, Meg C. Doherty et al. · Journal of the International AIDS Society Open access 2016 400
27 Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study Glenda Gray et al. · The Lancet Infectious Diseases Open access 20 May 2011 393
28 How well do global ocean biogeochemistry models simulate dissolved iron distributions? Alessandro Giulio Tagliabue, Olivier Aumont, Ros M. Death et al. · Global Biogeochemical Cycles Open access 28 Dec 2015 391
29 Determinants of Mortality in a Combined Cohort of 501 Patients With HIV-Associated Cryptococcal Meningitis: Implications for Improving Outcomes Joseph N Jarvis et al. · Clinical Infectious Diseases Open access 6 Dec 2013 381
30 Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study Edgar Turner Overton et al. · The Lancet Dec 2020 378
31 Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings Rishi K Gupta, Sebastian B Lucas, Katherine Fielding et al. · AIDS Open access 12 Aug 2015 375
32 Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control Stephen D Lawn, Landon Myer, Linda‐Gail Bekker et al. · AIDS 24 Jul 2006 369
33 Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design Stephen D Lawn, Landon Myer, Catherine Orrell et al. · AIDS 10 Nov 2005 362
34 Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort Stephen D Lawn, Motasim Badri, Robin Wood · AIDS 10 Nov 2005 357
35 Clinical Case Definitions for Classification of Intrathoracic Tuberculosis in Children: An Update Stephen M. Graham, Luís E. Cuevas, Patrick Jean‐Philippe et al. · Clinical Infectious Diseases Open access 25 Sep 2015 354
36 Childhood Pulmonary Tuberculosis Ben J. Marais, Robert Peter Gie, Hendrik Simon Schaaf et al. · American Journal of Respiratory and Critical Care Medicine 16 Feb 2006 348
37 Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa Stephen D Lawn, Landon Myer, David Edwards et al. · AIDS Open access 13 Aug 2009 347
38 Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa Stephen D Lawn, Landon Myer, Linda‐Gail Bekker et al. · AIDS 24 Jan 2007 347
39 Evaluation of Tuberculosis Diagnostics in Children: 1. Proposed Clinical Case Definitions for Classification of Intrathoracic Tuberculosis Disease. Consensus From an Expert Panel Stephen M. Graham et al. · The Journal of Infectious Diseases Open access 24 Mar 2012 330
40 Screening for Cryptococcal Antigenemia in Patients Accessing an Antiretroviral Treatment Program in South Africa Joseph N Jarvis, Stephen D Lawn, Monica Vogt et al. · Clinical Infectious Diseases Open access 17 Feb 2009 324
41 Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts Ben J. Marais et al. · The Lancet Infectious Diseases Open access 24 Mar 2013 319
42 Stigma reduction interventions in people living with HIV to improve health-related quality of life Galit Zeluf Andersson, Maria Reinius, Lars E. Eriksson et al. · The Lancet HIV Open access 24 Nov 2019 316
43 Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub‐Saharan Africa: a systematic review Katharina Kranzer, Darshini Govindasamy, Nathan Paul Ford et al. · Journal of the International AIDS Society ReviewOpen access Apr 2012 312
44 A Refined Symptom-Based Approach to Diagnose Pulmonary Tuberculosis in Children Ben J. Marais, Robert Peter Gie, Anneke Catharina Hesseling et al. · PEDIATRICS Nov 2006 307
45 Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions Lewis John Haddow, Robert Colebunders, Graeme Meintjes et al. · The Lancet Infectious Diseases Open access 26 Oct 2010 306
46 Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study Stephen D Lawn, Andrew D. Kerkhoff, Monica Vogt et al. · The Lancet Infectious Diseases Open access 18 Oct 2011 303
47 Evaluation of a Novel Point-of-Care Cryptococcal Antigen Test on Serum, Plasma, and Urine From Patients With HIV-Associated Cryptococcal Meningitis Joseph N Jarvis, Ann L. Percival, Sean K. Bauman et al. · Clinical Infectious Diseases Open access 21 Sep 2011 298
48 The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children Anneke Catharina Hesseling, Ben J. Marais, Robert Peter Gie et al. · Vaccine 2 Aug 2006 295
49 Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis Joseph N Jarvis, Graeme Meintjes, Kevin Brian Rebe et al. · AIDS Open access 14 Mar 2012 292
50 Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons Colleen Frances Kelley et al. · New England Journal of Medicine 27 Nov 2024 285

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.